TRVI Trevi Therapeutics, Inc.

8-K Current Report

Filed: March 9, 2026

Health Care

Pharmaceutical Preparations

Trevi Therapeutics, Inc. (TRVI) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• FDA End-of-Phase 2 meeting yielded full alignment on IPF-related chronic cough development plan — key regulatory de-risking milestone
• Two pivotal Phase 3 trials to run in parallel: ~300-patient/52-week trial (primary endpoint at 24 weeks) + ~130-patient/12-week trial

+2 more insights

Other Trevi Therapeutics, Inc. 8-K Filings

8-K Mar 17, 2026

Get deeper insights on Trevi Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.